{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,15]],"date-time":"2025-12-15T00:24:58Z","timestamp":1765758298017},"reference-count":15,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2011,12,1]],"date-time":"2011-12-01T00:00:00Z","timestamp":1322697600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Virol. Sin."],"published-print":{"date-parts":[[2011,12]]},"DOI":"10.1007\/s12250-011-3210-0","type":"journal-article","created":{"date-parts":[[2011,12,9]],"date-time":"2011-12-09T07:29:07Z","timestamp":1323415747000},"page":"386-392","source":"Crossref","is-referenced-by-count":4,"title":["Emerging trends of drug-resistant HIV-1 among drug-treated patients in former blood donors in Hubei, China: a three-year surveillance from 2004 to 2006"],"prefix":"10.1016","volume":"26","author":[{"given":"Jian","family":"Gong","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiao-qiong","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiao","family":"Tong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xi-hui","family":"Shen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rong-ge","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","published-online":{"date-parts":[[2011,12,10]]},"reference":[{"key":"3210_CR1","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1089\/08892220260190308","volume":"18","author":"A. Antinori","year":"2002","unstructured":"Antinori A, Zaccarelli M, Cingolani A, et al. 2002. Cross-resistance among nonnucleoside reverse transcriptase inhibitors limits recycling efavirenz after nevirapine failure. AIDS Res Hum Retrov, 18: 835\u2013838.","journal-title":"AIDS Res Hum Retrov"},{"key":"3210_CR2","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1177\/135965350200700301","volume":"7","author":"V. Calvez","year":"2002","unstructured":"Calvez V, Costagliola D, Descamps D, et al. 2002. Impact of stavudine phenotype and thymidine analogues mutations on viral response to stavudine plus lamivudine in ALTIS 2 ANRS trial. Antivir Ther, 7: 211\u2013218.","journal-title":"Antivir Ther"},{"key":"3210_CR3","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/j.ijantimicag.2008.10.010","volume":"33","author":"E. Clercq De","year":"2009","unstructured":"De Clercq E. 2009. Anti-HIV drugs: 25 compounds approved within 25 years after the discovery of HIV. Int J Antimicrob Ag, 33: 307\u2013320.","journal-title":"Int J Antimicrob Ag"},{"issue":"Suppl.1","key":"3210_CR4","first-page":"42","volume":"1","author":"T. Gingeras","year":"1996","unstructured":"Gingeras T, Mamtora G, Shen N, et al. 1996. Genetic analysis of HIV-1 plasma using high density oligonucleotide arrays and dideoxynucleotide sequencing. Antivral Therapy, 1(Suppl.1): 42.","journal-title":"Antivral Therapy"},{"key":"3210_CR5","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1093\/jac\/42.2.269","volume":"42","author":"K. Hertogs","year":"1998","unstructured":"Hertogs K, de Bethune M P, Miller V, et al. 1998. A rapid method for simultaneous detection of phenotypic resistance to inhibitors of protease and reverse transcriptase in recombinant human immunodeficiency virus type 1 isolates from patients treated with antiretroviral drugs. Antimicrob Agents Ch, 42: 269\u2013276.","journal-title":"Antimicrob Agents Ch"},{"key":"3210_CR6","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1128\/AAC.37.5.1095","volume":"37","author":"A. J. Japour","year":"1993","unstructured":"Japour A J, Mayers D L, Johnson V A, et al. 1993. Standardized peripheral blood mononuclear cell culture assay for determination of drug susceptibilities of clinical human immunodeficiency virus type 1 isolates. The RV-43 Study Group, the AIDS Clinical Trials Group Virology Committee Resistance Working Group. Antimicrob Agents Ch, 37: 1095\u20131101.","journal-title":"Antimicrob Agents Ch"},{"key":"3210_CR7","first-page":"62","volume":"16","author":"V. A. Johnson","year":"2008","unstructured":"Johnson V A, Brun-Vezinet F, Clotet B, et al. 2008. Update of the drug resistance mutations in HIV-1: Spring 2008. Top HIV Med, 16: 62\u201368.","journal-title":"Top HIV Med"},{"key":"3210_CR8","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1093\/nar\/29.1.296","volume":"29","author":"R. Kantor","year":"2001","unstructured":"Kantor R, Machekano R, Gonzales M J, et al. 2001. Human Immunodeficiency Virus Reverse Transcriptase and Protease Sequence Database: an expanded data model integrating natural language text and sequence analysis programs. Nucleic Acids Research, 29: 296\u2013299.","journal-title":"Nucleic Acids Research"},{"key":"3210_CR9","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1097\/00126334-200501010-00007","volume":"38","author":"D. Lecossier","year":"2005","unstructured":"Lecossier D, Shulman N S, Morand-Joubert L, et al. 2005. Detection of minority populations of HIV-1 expressing the K103N resistance mutation in patients failing nevirapine. J Acq Immune Defic Syndr, 38: 37\u201342.","journal-title":"J Acq Immune Defic Syndr"},{"key":"3210_CR10","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1089\/aid.2007.0144","volume":"24","author":"P. Liu","year":"2008","unstructured":"Liu P, Xiang K, Tang H, et al. 2008. Molecular epidemiology of human immunodeficiency virus type 1 and hepatitis C virus in former blood donors in central China. AIDS Res Hum Retrov, 24: 1\u20136.","journal-title":"AIDS Res Hum Retrov"},{"key":"3210_CR11","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1128\/AAC.49.5.1739-1744.2005","volume":"49","author":"A. G. Marcelin","year":"2005","unstructured":"Marcelin A G, Flandre P, Pavie J, et al. 2005. Clinically relevant genotype interpretation of resistance to didanosine. Antimicrob Agents Ch, 49: 1739\u20131744.","journal-title":"Antimicrob Agents Ch"},{"key":"3210_CR12","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1093\/nar\/gkg100","volume":"31","author":"S. Y. Rhee","year":"2003","unstructured":"Rhee S Y, Gonzales M J, Kantor R, et al. 2003. Human immunodeficiency virus reverse transcriptase and protease sequence database. Nucleic Acids Research, 31: 298\u2013303.","journal-title":"Nucleic Acids Research"},{"key":"3210_CR13","doi-asserted-by":"crossref","first-page":"906","DOI":"10.7326\/0003-4819-128-11-199806010-00008","volume":"128","author":"R. W. Shafer","year":"1998","unstructured":"Shafer R W, Winters M A, Palmer S, et al. 1998. Multiple concurrent reverse transcriptase and protease mutations and multidrug resistance of HIV-1 isolates from heavily treated patients. Ann Intern Med, 128: 906\u2013911.","journal-title":"Ann Intern Med"},{"key":"3210_CR14","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1086\/432916","volume":"192","author":"A. M. Wensing","year":"2005","unstructured":"Wensing A M, van de Vijver D A, Angarano G, et al. 2005. Prevalence of drug-resistant HIV-1 variants in untreated individuals in Europe: implications for clinical management. J Infect Dis, 192: 958\u2013966.","journal-title":"J Infect Dis"},{"key":"3210_CR15","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1016\/S0140-6736(98)12262-6","volume":"354","author":"S. Yerly","year":"1999","unstructured":"Yerly S, Kaiser L, Race E, et al. 1999. Transmission of antiretroviral-drug-resistant HIV-1 variants. Lancet, 354: 729\u2013733.","journal-title":"Lancet"}],"container-title":["Virologica Sinica"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12250-011-3210-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12250-011-3210-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12250-011-3210-0","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,11]],"date-time":"2023-06-11T17:05:04Z","timestamp":1686503104000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12250-011-3210-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,12]]},"references-count":15,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2011,12]]}},"alternative-id":["3210"],"URL":"https:\/\/doi.org\/10.1007\/s12250-011-3210-0","relation":{},"ISSN":["1674-0769","1995-820X"],"issn-type":[{"value":"1674-0769","type":"print"},{"value":"1995-820X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,12]]}}}